MedPath

Effect of Ipragliflozin, a new oral hypoglycemic agent, on body composition in patients with diabetes

Not Applicable
Conditions
type 2 diabetes
Registration Number
JPRN-UMIN000014775
Lead Sponsor
Keio University School of Medicine, Internal Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Contraindication for Ipragliflozin Patients who had been treated with metformin or GLP-1 analogues Pregnant woman

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ean body mass
Secondary Outcome Measures
NameTimeMethod
body weight fasting plasma glucose HbA1c free fatty acid (24 fraction)
© Copyright 2025. All Rights Reserved by MedPath